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HISTORY OF PRESENT ILLNESS 
ABSTRACT 
Chronic myeloid leukemia (CML) is a myeloproliferative disease that generates from 
malignant transformation of pluripotent hematopoietic stem cells. First line treatment for 
CML is the tyrosine kinase inhibitor (TKI), imatinib. For patients resistant or intolerant to 
imatinib, other TKIs, dasatinib, nilotinib, and ponatinib, are approved treatments. Patients 
who are resistant or intolerant to other agents are started on ponatinib as a last line 
option. Common adverse events of ponatinib are hypertension, dry skin, rash, abdominal 
pain, constipation, and nausea. More serious adverse effects include cardiovascular 
effects, fluid retention, pancreatitis, severe myelosuppression, and hepatotoxicity. 
Treatment for these adverse effects can include interrupting ponatinib therapy and 
providing symptomatic and supportive care. Reintroduction of agent can be considered 
when the serious event has resolved or the potential benefit of resuming therapy is 
judged to outweigh the risk. The patient is a 65 year old Caucasian male with a history of 
imatinib-resistant CML. The patient was started on ponatinib 45mg approximately 3 
months prior to presentation after failure of previous regimens. He requires platelet 
transfusions for ponatinib associated thrombocytopenia. He presents with 4 days of new 
right flank pain with radiation to his right groin. Evidence of pancreatitis was found on 
endoscopic retrograde cholangiopancreatography (ERCP). LFTs were elevated on 
admission. The patient had no history of alcohol or steroid use. Ponatinib was 
discontinued on admission and within three days the patient’s symptoms of 
thrombocytopenia, pancreatitis and hepatotoxicity began to resolve.  After complete 
resolution of the pancreatitis, the patient was restarted on ponatanib 15mg as an 
outpatient. Patients started on ponatinib should have their serum lipase, amylase, liver 
enzymes, and platelets checked every 2 weeks for the first 2 months and then monthly. 
By checking levels regularly it may allow the physicians to decrease the dose before 
complications arise that may require hospitalization. Signs and symptoms of pancreatitis 
should also be monitored and started on a low dose to avoid complications. 
TP (the patient), a 65 year old Caucasian male, presented to the emergency 
department (ED) on 6/3 with 4 days of right flank pain with radiation to his right 
groin. His pain was variable in severity with no associated nausea, vomiting, 
constipation, or diarrhea. In the ED, TP was also found to have thrombocytopenia 
and anemia, with platelet count of 6,000/µL, Hgb 12.3g/dL, and Hct 35.9%. TP 
displayed no symptoms of overt bleeding. Elevated transaminases were also found 
on admission; AST was 284 IU/L, ALT was 185 IU/L with no evidence of jaundice or 
liver failure. 
Past medical history: Imatinib-resistant CML, platelet transfusion dependent 
thrombocytopenia, bilateral non-obstructing nephrolithiasis, GERD, chronic anemia, 
hypertension, tubular adenoma, marijuana and tobacco use (52 pack year history; 
quit 1/2013; currently uses electronic cigarettes) 
Medications prior to admission:   
 
ANALYSIS OF THE REACTION 
SEVERITY 
After ponatinib discontinuation, and the administration of fluid replacement and blood 
transfusions, transaminases, platelets and symptoms of pancreatitis normalized. 
Following hospital admission, the patient was restarted on a decreased dose of 15 
mg daily which was increased after a week to 30 mg. After re-initiation, there were 
no signs of pancreatitis or elevated transaminases. Due to low platelet count (33,000 
platelets/µL), ponatinib therapy was again discontinued the following month. When 
platelet count increased again, the patient was restarted on 15 mg daily. Ponatinib 
was eventually discontinued due to lack of efficacy and bosutinib was initiatied. 
REFERENCES & DISCLOSURES 
For patients who are resistant or intolerant to imatinib, dasatinib, or nasatinib, 
physicians could initiate ponatinib. Patients started on CML treatment are routinely 
monitored for thrombocytopenia and myelosuppression. Myelosuppresion typically 
occurs within the first 4 weeks of therapy and is more common in patients with 
advanced disease.3 In the 43 patients with chronic phase CML, treatment-related 
thrombocytopenia of grade 3 or more occurred in 12 patients (28%).2  
Ponatinib can also cause acute pancreatitis and liver dysfunction. Dose-limiting toxic 
effects included pancreatic events, with pancreatitis observed in 14% of patients. 
Patients should be educated and monitored on signs and symptoms of pancreatitis. 
Cortes et. al discussed that thrombocytopenia and pancreatic are self-limiting once 
the drug is discontinued.2 Discontinuation of ponatinib should resolve pancreatitis 
symptoms within 2 weeks.2 There is no research evaluating restarting the medication. 
However, it is recommended to decrease the dose and serum lipase levels should be 
checked every 2 weeks for the first 2 months of initiation, and then monthly 
thereafter.3 For patients with history of alcohol abuse, additional serum monitoring 
should be considered.4 This case showed that discontinuation of ponatinb allowed the 
patient’s labs to normalize. Due to lack of an available alternative agent, the patient 
was restarted on ponatinib until patient eventually failed therapy. 
On October 31st, Ariad Pharmaceuticals suspended production of  ponatinib due to 
case reports of life-threatening blood clots and severe narrowing of blood vessels 
linking the drug to fatal heart attacks and strokes within two weeks of initiation.5 
Ponatinib can only be requested for compassionate use in U.S. however, the 
Pharmacovigilance Risk Assessment Committee of the European Medicines Agency  
have decided to keep ponatinib on the market with a stronger warning precautions.6 
OUTCOMES 
The adverse effects were severe. The patient was admitted due to pain, 
thrombocytopenia and elevated transaminases. He required daily monitoring for 
bleeding, fever and pain. He required daily platelet transfusions and hydration until 
ERCP could be performed. Due to the need for an ERCP procedure, the patient 
spent additional time in the hospital.  
CASE REPORT 
DISCUSSION 
1. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmcol Ther 1981:30:239-245. 
2. Cortes JE, Kanarjian H, Shah N, et al. Ponatinib in refractory philadelphia chromosome-positive leukemias. NEJM. 2012:367;22:2075-2086 
3. Fausel C.A., Kiel P.J. (2011). Chapter 143. Chronic Leukemias. J.T. DiPiro.(Eds), Pharmacotherapy: A Pathophysiologic Approach, 8e. 
4. Iclusig™ [package insert]. Cambridge, MA. ARIAD Pharmaceuticals, Inc. 2012. 
5. FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. “Safety 
Communication October31st, 2013.” Retrieved from url: www.fda.gov/Drugs/DrugSafety/ucm373040.htm 
6. Nelson, Roxanne. EU Strengthens Warning on Ponatinib. Medscape Medical News. November 8th, 2013. Retrieved from url: 
www.medscape.com/viewarticle/814078 
In the ED (6/3/13), medications used for symptom relief included: 
 
 
 
Due to low platelet count in ED (6,000 platelets/µL) and elevated transaminases, 
ponatinib was held. A computed tomography (CT) scan showed an increase in 
intra and extrahepatic ducts, common duct, and pancreatic ducts extending to the 
ampulla. After an ERCP, evidence of acute pancreatitis was found. Ponatinib was 
discontinued on admission (6/4/13), and pancreatitis resolved. Platelet 
transfusions were given until platelet count increased. Ponatinib was restarted at 
a lower dose of 30 mg following hospital discharge. 
• Tramadol 50 mg PO TID for pain 
• Ponatinib 45 mg PO daily for CML 
• Ondansetron 8 mg PO BID prn N 
• Docusate NA 100 mg PO BID 
• Dronabinol 5 mg PO BID ac  
• Hydrocodone/APAP 5/500 mg PO Q6H 
prn pain 
 
 
 
 
 
 
 
 
 
• Ammonium Lactate 12% lotion to skin 
BID for dry skin 
• Amlodipine 5 mg PO daily for HTN 
• Sinus Rinse 1 packet nasally BID prn 
• PEG 3350 1 TBSP daily mixed in 8 oz 
of water, juice, soda or coffee 
• Fluticasone 50 mcg spray once in each 
nostril daily 
Use of the Naranjo adverse drug reaction probability scale1,2 indicated a probable 
relationship with thrombocytopenia (score of 8) and elevated transaminases (score 
of 7). The scale assigned a possible relationship with pancreatitis (score of 4) and 
ponatinib in this patient. While the Naranjo scale1 only found a possible-probable 
relationship with the adverse events, they were likely to be drug induced. Other 
causes of the adverse effects were considered and excluded. Patient was not 
taking any other medications that could cause pancreatitis, thrombocytopenia 
and/or elevated transaminases and he had no history of alcohol or steroid use. 
ERCP ruled out cancer and granuloma. Pancreatitis resolved upon discontinuation 
of ponatinib, so galls stones as a cause was ruled out.  
• PEG 3350 1 TBSP PO  
• Ammonium Lactate 12% lotion to skin 
• Docusate 100mg PO 
• Fluticasone 50 mcg in each nostril  
 
 
 
 
• Ondansetron 4 mg IV x 3 doses 
• Pantoprazole 40 mg PO x 2 doses 
• Tramadol 50 mg PO x 4 doses 
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Graphs depict changes in AST, ALT, and platelet levels over time. Ponatinib was initiated 
on 2/13, discontinued 6/4 after presenting to the ED, and resumed at a lower dose on 
6/8. Due to the drop in platelet count (6/9) and rise in LFTs, ponatinib was discontinued 
again and restarted on 6/14/13. Platelet transfusions (    ) were administered until 
platelets were ≥ 25,000 for ERCP. 
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